|View printer-friendly version|
“Current treatment options for patients with liver cancer remain unsatisfactory. We are encouraged that in this trial, BGB-A317 demonstrated preliminary anti-tumor activity in patients with hepatitis B virus-positive HCC, a subtype typically associated with poor prognosis,” commented
“We are pleased to report preliminary data from HCC patients enrolled in our Phase 1 trial of BGB-A317. We view these early results as encouraging, particularly in this high unmet need indication, and we believe the preliminary safety profile and anti-tumor activity support continued development of BGB-A317 in patients with advanced HCC. We look forward to more mature data in the coming months from these patients, as well as data from additional cohorts of patients in this trial,” commented
Summary of Results from the Ongoing Phase 1 Study
The multi-center, open-label Phase 1a/1b trial of BGB-A317 as monotherapy in advanced solid tumors is being conducted in
Data presented at WCGI 2017 are from 40 patients with advanced HCC who were treated with BGB-A317 at a dose of 5 mg/kg every three weeks. The majority of the enrolled patients (34/40 patients) had a hepatitis B virus (HBV) infection. At the time of the data cutoff on
Adverse events (AEs) assessed by the investigator to be related to treatment occurred in 21 patients (53%). Of those, rash (20%), pruritus (13%), increased aspartate aminotransferase (AST) (8%), fatigue (5%), hypothyroidism (5%), and decreased appetite (5%) were reported in more than one patient. All of the treatment-related AEs were grades 1 or 2, with the exception of one grade 5 event of acute hepatitis assessed by the investigator to be related to BGB-A317. This patient had widely metastatic disease and died five weeks after receiving his first and only dose of BGB-A317 and subsequently developing evidence of disease progression.
At the time of the data cutoff, the efficacy evaluation was early, and 27 patients were evaluable for response. Twelve of the evaluable patients remained on treatment and the majority (seven) of these had only one tumor assessment at the time of the data cutoff. Confirmed and unconfirmed partial responses (PRs) were observed in three patients, all with HBV-positive HCC. One PR was confirmed before the cutoff date, one was confirmed one day following the cutoff date, and one was unconfirmed and the patient remained on therapy. Nine patients achieved stable disease, some of whom also had significant reductions in alpha-fetoprotein levels.
BGB-A317 is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1, and we believe it may be differentiated from the currently approved PD-1 antibodies, as the ability to bind to Fc gamma receptors has been specifically engineered out. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of various cancers.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the encouraging clinical data of BGB-A317 and our future development plans for BGB-A317. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including
Lucy Li, Ph.D. +1 781-801-1800 firstname.lastname@example.org email@example.com